Boston Scientific Restores Key Operations After Cyberattack

The company said products are moving through its distribution network at or above normal levels as the Marlborough, Mass., company works to fulfill customer orders, reduce backlogs and accelerate the delivery of products.

WSJ • 4 hours ago

Boston Scientific Corporation (BSX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Boston Scientific Corporation (BSX) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Seeking Alpha • 3 hours ago

Boston Scientific says cyberattack likely to hurt 2026 sales, profit

Boston Scientific ‌said on Tuesday a cybersecurity incident ​that disrupted ​manufacturing and order shipments ⁠globally is likely ​to have a ​material impact on its third-quarter and full-year ​2026 results.

Reuters • Sep 8, 2026

Boston Scientific Slammed After Cyberattack Hamstrings Sales, Profit

Boston Scientific said Tuesday a cybersecurity incident is likely to have a material impact on its third-quarter and full-year results.

Investors Business Daily • Sep 8, 2026

Boston Scientific ‘Unlikely to Meet' Earnings Guidance After Cyberattack. Stock Falls.

Boston Scientific stock falls as the medical device maker says a recent cyberattack may make it hard to hit quarterly and full-year guidance targets.

Barrons • Sep 8, 2026

Boston Scientific Says It Won't Meet 2026 Guidance After Cyberattack

Boston Scientific Corporation (NYSE:BSX) anticipates a material hit to its third-quarter and full-year 2026 financial results following an August cybersecurity incident that disrupted global operations.

Benzinga • Sep 8, 2026

Boston Scientific's 2026 Growth Outlook Weakens: Is Recovery Ahead?

BSX's 2026 outlook weakens as WATCHMAN and EP face pressure, but seven launches and cost savings are likely to fuel recovery by 2028.

Zacks Investment Research • Sep 8, 2026

Boston Scientific Won't Meet Guidance Due to Cyberattack

Boston Scientific said it likely won't meet its financial guidance due to the cyberattack that has disrupted its operations, sending shares of the medical-technology company down sharply in premarket trading.

WSJ • Sep 8, 2026

Boston Scientific's ICVT Business Gains Momentum: Can Growth Continue?

BSX's ICVT sales have jumped 15% as coronary therapies gained traction, while new devices and deals could extend its growth momentum.

Zacks Investment Research • Sep 4, 2026

Cyberattack & Weak 2026 Outlook Weigh on BSX: Is the Stock a Sell?

Boston Scientific faces a cyberattack, weaker 2026 guidance and business pressures, raising concerns over its outlook and whether investors should exit.

Zacks Investment Research • Sep 3, 2026